---
title: Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With
  Internal Tandem Duplication Mutation of FLT3
date: '2024-03-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38471061/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240313180649&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Although the overall improvement in RFS was not statistically
  significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or
  post-HCT who received gilteritinib treatment. To our knowledge, these data are among
  the first to support the effectiveness of MRD-based post-HCT ...'
disable_comments: true
---
CONCLUSION: Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT ...